Win Medica
Greek pharmaceutical company (founded 2008, Athens) that in-licenses, registers, and commercializes innovative treatments across 11 therapeutic areas for Greek patients and 42+ international markets, supported by a new 500 million-tablet Tripoli manufacturing facility and 14+ multinational pharma partnerships.
- Company typePrivate
- Founded2008
- HeadquartersAthens, Greece
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Win Medica does
Win Medica A.E. is a Greek pharmaceutical company, founded in 2008 and headquartered in Marousi, Athens, that specializes in the in-licensing, registration, and commercialization of innovative pharmaceutical treatments for the Greek and broader international markets. The company operates across 11 therapeutic areas organized around four focus pillars: (1) specialty medicines in oncology, hematology, immunology and urology; (2) chronic care branded generics for hypertension, diabetes, cholesterol and obesity; (3) vaccines and consumer health, including the Seqirus-partnered FLUAD influenza vaccine and Pharmanutra-partnered SiderAL and UltraMag Oro supplements; and (4) advanced manufacturing and R&D, anchored by a new high-potency facility in Tripoli with 500 million tablets/year capacity. Its revenue model is built on prescription pharmaceutical sales and OTC distribution through Greek pharmacies and healthcare providers, supplemented by proprietary sub-brands such as Sofargen (wound care), Valetonina (sleep aid), and Tokovys (smoking cessation), with go-to-market executed via an enterprise field-sales motion targeting HCPs and a dedicated healthcare-professional portal.
Strategically, Win Medica is a subsidiary of the ELPEN Group, participating in a combined 400+ million euro investment program with sister companies DEMO ABEE and FARAN that is creating over 1,500 direct and indirect high-specialization jobs. The firm has grown to 210-220+ professionals serving approximately 650,000 patients annually across 42+ countries, with a portfolio of 87+ registered products. Its competitive position rests on established Greek regulatory and distribution infrastructure, vertically integrated manufacturing now anchored by the Tripoli plant, and a broad alliance network with 14+ multinational pharmaceutical partners, though no revenue, financial performance, or AI/ML capabilities are publicly disclosed.
Win Medica firmographics
Firmographics- Name
- Win Medica
- Legal name
- WIN MEDICA A.E.
- Website
- https://winmedica.gr
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Greek pharmaceutical company (founded 2008, Athens) that in-licenses, registers, and commercializes innovative treatments across 11 therapeutic areas for Greek patients and 42+ international markets, supported by a new 500 million-tablet Tripoli manufacturing facility and 14+ multinational pharma partnerships.
- Ownership category
- akta.pro rank
Where Win Medica is headquartered
LocationHeadquarters
- HQ city
- Athens
- HQ country
- Greece
- HQ region
- Europe
Offices2 records
Markets served
Win Medica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical product sales: Win Medica develops and delivers treatments across specialty medicines, chronic care, and vaccines & consumer health. They in-license, register, and commercialize innovative treatments from global pharmaceutical partners.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Win Medica product offering
Product offeringCore offering
Win Medica is a Greek pharmaceutical company that in-licenses, registers, and commercializes innovative pharmaceutical treatments in partnership with leading global pharmaceutical companies. The company develops, manufactures, and distributes a portfolio of 87+ prescription medicines, OTC products, medical devices, and dietary supplements across 11 therapeutic areas including specialty medicines (oncology, hematology, immunology, urology), chronic care (hypertension, diabetes, cholesterol, obesity), and vaccines/consumer health.
Product overview
Win Medica is a Greek pharmaceutical company (since 2008) specializing in in-licensing, registration, and commercialization of innovative treatments. The company operates a portfolio of 87+ pharmaceutical products including prescription medications, OTC products, medical devices, and dietary supplements. Their therapeutic focus spans four areas: (1) Specialty medicines in oncology, hematology, immunology, and urology; (2) Chronic care including branded generics for hypertension, diabetes, cholesterol and obesity; (3) Vaccines and consumer health; and (4) Advanced manufacturing via their new Tripoli facility with 500 million tablet capacity. Key branded products include Sofargen® (Repair, Spray, Gel) wound care medical devices, SiderAL® iron supplements (Forte, Folico, Sport, Drops), Valetonina® melatonin/valerian sleep aid, UltraMag® Oro magnesium supplement, Vitrex-Easydrip insulin needles, and On Call glucose meters. The company holds strategic partnerships with multinational pharmaceutical companies including Seqirus, Novartis, Accord, Viatris, Servier, and others to distribute their products in the Greek market.
Differentiator
Problem solved
Functional benefit
Brands
- Sofargen: Wound care product line including Sofargen Repair (water-based dressing with hyaluronic acid and silver sulfadiazine), Sofargen Spray (powder for minor wounds), and Sofargen Gel
- SiderAL
- Valetonina
- UltraMag Oro
- Tokovys
Products and services
- Sofargen® Repair Water-based wound dressing containing hyaluronic acid and silver sulfadiazine for topical treatment of skin lesions including abrasions, cuts, wounds, burns, and superficial wounds.
- Sofargen® Spray Medical device in powder form containing kaolin and silver sulfadiazine for treatment of minor skin wounds including cuts, abrasions, and superficial wounds.
- Sofargen® Gel Medical device gel with silver sulfadiazine and high water content (>95%) for wound care, maintaining wound moisture and preventing infections.
- Valetonina® Dietary supplement combining melatonin and valerian with innovative dual-release technology for treatment of insomnia and jet lag.
- UltraMag® Oro Magnesium supplement utilizing patented sucrosomal technology for enhanced absorption to treat magnesium deficiency symptoms including insomnia, fatigue, muscle cramps, and headaches.
- Vitrex - Easydrip High-tech pen-type insulin scalpers and needles from Scandinavia, compatible with most insulin devices and pens on the market. Available in 30G, 31G, and 32G sizes.
- Tokovys® Smoking cessation treatment containing cytisinicline.
- SiderAL® Sport Iron and vitamin B-complex supplement using sucrosomal technology for athletes and those with increased physical or mental demands.
- On Call Extra Glucose meter for diabetes monitoring.
- On Call Vivid Glucose meter for diabetes monitoring.
Quantifiable outcome
- 500 million tablets per year manufacturing capacity
- +2 more outcomes
Companies that use Win Medica
Customer profileNamed customers2 records
Segments5 records
Win Medica technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Win Medica partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core.
- SeqiruscoreStrategic alliance bringing Seqirus vaccine products to the Greek market, including FLUAD influenza vaccine
- NovartiscoreStrategic alliance with Novartis for distribution of pharmaceutical products in Greece
- AccordcoreStrategic alliance with Accord for generic pharmaceutical products
- PharmanutracorePartnership with Pharmanutra for consumer health products including UltraMag Oro and SiderAL products
- AdamedcoreStrategic alliance with Adamed for pharmaceutical product distribution
- MabxiencecoreStrategic partnership with Mabxience for biosimilar and pharmaceutical products
- ChemocoreStrategic alliance with Chemo for pharmaceutical product distribution
- MediscoreStrategic partnership with Medis for pharmaceutical products
- SofarcoreStrategic alliance with Sofar for pharmaceutical product distribution
- WeldingcoreStrategic partnership with Welding for pharmaceutical products
- ViatriscoreStrategic alliance with Viatris for generic and specialty pharmaceutical products
- ServiercoreStrategic partnership with Servier for pharmaceutical product distribution
- PolpharmacoreStrategic alliance with Polpharma for generic pharmaceutical products
- Midas PharmacoreStrategic partnership with Midas Pharma for pharmaceutical products
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Win Medica competitors and assessment
Company assessmentBroad incumbents
- Viatris: Global pharmaceutical company formed from Mylan-Pfizer Upjohn, focused on generics and specialty. Strategic partner of Win Medica (supplying generic and specialty products to the Greek market) and a direct competitor in the broader European branded-generics space.
- Stada Arzneimittel: European-focused generics and specialty pharma leader with consumer health business. Closely comparable business model combining generics, specialty, and consumer health across European markets with similar product breadth.
- Novartis: Global originator pharmaceutical leader with deep Greek market presence. Strategic distribution partner of Win Medica and a broad incumbent whose therapeutic areas (oncology, immunology, chronic care) overlap with Win Medica's portfolio.
Regional players
- Polpharma: Polish pharmaceutical manufacturer and one of the largest generic producers in Central Europe. Strategic partner of Win Medica and a comparable regional generic-and-specialty player with cross-border distribution reach.
- Adamed Pharma: Polish pharmaceutical company with branded generics, specialty, and consumer health operations across Central/Eastern Europe. Strategic partner of Win Medica and comparable in product mix and regional orientation.
- Krka: Slovenian-headquartered generic pharmaceutical manufacturer with strong presence across Central, Eastern, and Southern Europe. Comparable vertically integrated generics + specialty model serving similar regional markets.
Direct peers
- FARAN ABEE: Sister company within ELPEN Group focused on pharmaceutical manufacturing and distribution. Co-investor in the €400M+ strategic investment plan with Win Medica, operating in overlapping therapeutic segments.
- Mabxience: Global biosimilars developer and manufacturer. Strategic partner of Win Medica and a comparable in-licensing/partner-driven player bringing biologic products into regional European markets, with overlapping specialty therapeutic focus.
- ELPEN Pharmaceutical: Parent company of Win Medica and the largest Greek pharmaceutical manufacturer. Directly comparable vertically integrated model combining manufacturing, R&D, and domestic commercialization of branded generics and specialty products.
- DEMO ABEE: Sister company under ELPEN Group and one of Greece's largest injectable pharmaceutical manufacturers. Joint strategic investor in the Tripoli facility and directly comparable in product categories (sterile injectables, hospital specialty).
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks4 records
Key highlights6 records
Customer concentration
Win Medica social profiles
Digital presenceWin Medica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Win Medica leadership team
Management profileNumber of profiles
Win Medica funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Win Medica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Win Medica
What does Win Medica do?
Win Medica is a Greek pharmaceutical company that in-licenses, registers, and commercializes innovative pharmaceutical treatments in partnership with leading global pharmaceutical companies. The company develops, manufactures, and distributes a portfolio of 87+ prescription medicines, OTC products, medical devices, and dietary supplements across 11 therapeutic areas including specialty medicines (oncology, hematology, immunology, urology), chronic care (hypertension, diabetes, cholesterol, obesity), and vaccines/consumer health.
Is Win Medica a public or private company?
Win Medica is a private company. It is classified as corporate owned and is currently operating.
When was Win Medica founded?
Win Medica was founded in 2008. It employs 51 to 100 people.
Where is Win Medica based?
Win Medica is headquartered in Athens, Greece, in the Europe region.
How does Win Medica make money?
One revenue line is on record: pharmaceutical product sales.
Who are Win Medica's main competitors?
Broad incumbents on record are Viatris, Stada Arzneimittel and Novartis. Regional players are Polpharma, Adamed Pharma and Krka. Direct peers are FARAN ABEE, Mabxience, ELPEN Pharmaceutical and DEMO ABEE.
Does Win Medica have an API?
No public API is recorded for Win Medica.